About:
Abiosciences is using single-cell technology to understand the molecular basis of human diseases. Discovery of new drug targets and therapies can be fueled by building by the pioneering technology that enables information of gene expression and protein abundance of a diseased single cell. By combining their single cell techniques and metadata analysis platform, Abiosciences is developing proprietary drug targets that can be licensed, accelerating the drug discovery process and lowering overall costs. Abiosciences either invites interested partners to license therapeutics leads or co-develops them. In addition, Abiosciences offers bioinformatics services to aid other researchers process the large amount of data received through single-cell omics.